People with HIV and hepatitis C are no longer at higher risk of end-stage liver disease than people with hepatitis C alone, and the trend is probably associated with the improved effectiveness of antiretroviral treatment, a French study has reported in the journal Hepatology.
Living with HIV and other diseases, cancer or opportunistic infections
News
January 15, 2019
Resource
November 21, 2018
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels.
Resource
November 14, 2018
The purpose of this guide is to provide a resource for clinicians on the ground who manage HIV and TB clients on a daily basis.
Event
November 14, 2018
Known as the “African CROI” the INTEREST Conference brings together scientists involved in HIV treatment, pathogenesis, and prevention research in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents.
Blog
October 29, 2018
Of no surprise to those in the HIV field, the epidemic continues to be fueled by stigma, none more evident than among key and mobile populations, such as people who inject drugs and sex workers. Speakers at the Southern African HIV Clinicians Society conference shared their experiences in working with these groups and challenged participants to view them as people – and not merely a public health problem.
Resource
October 26, 2018
Cryptococcal disease is an opportunistic infection that occurs primarily among people with advanced HIV disease and is an important cause of morbidity and mortality in this group.
Resource
October 26, 2018
Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment. New WHO interim guidelines contain recommendations regarding preferred first-line regimens for adults, adolescents and children initiating ART, which now include DTG and RAL.
Resource
October 18, 2018
The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics,
Resource
September 12, 2018
The Global Fund Results Report 2018 demonstrates that 27 million lives have been saved by the Global Fund partnership and includes key annual results achieved in countries where the Global Fund invests, including the 17.5 million people that received antiretroviral therapy for HIV, the 5 million people tested and treated for TB, and the 197 million mosquito nets distributed to prevent malaria.
News
September 12, 2018
The Global Fund to Fight AIDS, Tuberculosis and Malaria released a report today demonstrating that 27 million lives have been saved by the Global Fund partnership. The report shows tremendous progress that has been achieved by efforts to end the epidemics, while highlighting new threats.
